Literature DB >> 2476613

Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to beta-blocking agents in patients with stable angina pectoris.

J H Svendsen1, J Aldershvile, U Abildgaard, O Amtorp.   

Abstract

Twenty-four patients with severe stable angina pectoris were included in a randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of a controlled-release preparation of isosorbide-5-mononitrate (ISMN-CR) 60 mg once daily or twice daily as adjunctive treatment to a beta blocker. In bicycle ergometer exercise tests performed 4 h after study drug intake, total exercise time and time until 1-mm ST-depression increased significantly during both regimens as compared with placebo (p less than 0.05). However, only the 60-mg once-daily regimen was significantly better than placebo with regard to time until angina pectoris. The results indicate that ISMN-CR 60 mg once daily is effective as adjunctive to beta-blocker treatment, and nitrate tolerance appeared to develop during the twice-daily regimen. In 10 of the patients, the effect of additional sublingual nitroglycerin (NTG) was studied. Exercise time after NTG remained remarkably constant throughout all study periods. Exercise time was significantly prolonged after additional NTG and independent of the dose level of ISMN-CR. This indicates that cross-tolerance to NTG was not induced during sustained treatment with ISMN-CR.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476613     DOI: 10.1097/00005344-198909000-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed?

Authors:  T O Klemsdal; K Gjesdal
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 2.  Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.

Authors:  N S Gunasekara; S Noble
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 3.  Combination and triple therapy in patients with stable angina pectoris not adequately controlled by optimal β-blocker therapy.

Authors:  W E M Kok; F C Visser; C A Visser
Journal:  Neth Heart J       Date:  2002-11       Impact factor: 2.380

Review 4.  Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design.

Authors:  Rosita Zakeri; James A Levine; Gabriel A Koepp; Barry A Borlaug; Julio A Chirinos; Martin LeWinter; Peter VanBuren; Victor G Dávila-Román; Lisa de Las Fuentes; Prateeti Khazanie; Adrian Hernandez; Kevin Anstrom; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2015-01       Impact factor: 8.790

Review 5.  Clinical experience with Imdur in angina pectoris. A review.

Authors:  G Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.